MXPA05007886A - Vacunas para la mucosa con adyuvante de quitosan y antigenos para meningococo. - Google Patents

Vacunas para la mucosa con adyuvante de quitosan y antigenos para meningococo.

Info

Publication number
MXPA05007886A
MXPA05007886A MXPA05007886A MXPA05007886A MXPA05007886A MX PA05007886 A MXPA05007886 A MX PA05007886A MX PA05007886 A MXPA05007886 A MX PA05007886A MX PA05007886 A MXPA05007886 A MX PA05007886A MX PA05007886 A MXPA05007886 A MX PA05007886A
Authority
MX
Mexico
Prior art keywords
mucosal
compositions
meningitidis
chitosan
conjugated
Prior art date
Application number
MXPA05007886A
Other languages
English (en)
Inventor
Baudner Barbara
Original Assignee
Chiron Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Srl filed Critical Chiron Srl
Priority claimed from PCT/IB2004/000673 external-priority patent/WO2004067033A1/en
Publication of MXPA05007886A publication Critical patent/MXPA05007886A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invencion se refiere a las composiciones inmunogenicas para el suministro a las mucosas que comprende sacaridos capsulares de al menos dos de los serogrupos A, C, W135 e Y de la N. meningitidis. Se prefiere que los sacaridos capsulares en las composiciones de la invencion se conjuguen a las proteinas portadoras y/o sean oligosacaridos. Se prefieren en particular los antigenos de oligosacaridos conjugados. La invencion proporciona tambien composiciones inmunogenicas que comprenden (a) un antigeno de sacaridos capsular de N.meningitidis, y (b) un adyuvante de quitosan. La composicion comprende preferiblemente (c) uno o mas antigenos y/o d) uno o mas adyuvantes adicionales. Las composiciones son particularmente adecuadas para el suministro A las mucosas que incluye el suministro intranasal. El uso de quitosan y/o adyuvantes de toxinas que ribosilan el ADP mejora las respuestas inmunes de las mucosas anti-meningococo y pueden cambiar la propension Th1/Th2 de las respuestas.
MXPA05007886A 2003-01-30 2004-01-30 Vacunas para la mucosa con adyuvante de quitosan y antigenos para meningococo. MXPA05007886A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0302218.3A GB0302218D0 (en) 2003-01-30 2003-01-30 Vaccine formulation & Mucosal delivery
PCT/IB2003/002382 WO2003094834A2 (en) 2002-05-14 2003-05-14 Mucosal vaccines with chitosan adjuvant and meningococcal antigens
PCT/IB2004/000673 WO2004067033A1 (en) 2002-05-14 2004-01-30 Mucosal meningococcal vaccines

Publications (1)

Publication Number Publication Date
MXPA05007886A true MXPA05007886A (es) 2005-09-21

Family

ID=9952172

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05007886A MXPA05007886A (es) 2003-01-30 2004-01-30 Vacunas para la mucosa con adyuvante de quitosan y antigenos para meningococo.

Country Status (13)

Country Link
US (1) US8926992B2 (es)
EP (2) EP1506008B1 (es)
JP (4) JP4696260B2 (es)
CN (1) CN100579580C (es)
AU (1) AU2003233128B2 (es)
BR (2) BR0310062A (es)
CA (1) CA2485992C (es)
ES (2) ES2328128T3 (es)
GB (1) GB0302218D0 (es)
MX (1) MXPA05007886A (es)
NZ (1) NZ536715A (es)
RU (2) RU2004136299A (es)
WO (1) WO2003094834A2 (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9513371D0 (en) * 1995-06-30 1995-09-06 Biocine Spa Immunogenic detoxified mutant toxins
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
GB0302218D0 (en) * 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
WO2003094960A2 (en) * 2002-05-14 2003-11-20 Chiron Srl Mucosal combination vaccines for bacterial meningitis
DE60328481D1 (de) * 2002-05-14 2009-09-03 Novartis Vaccines & Diagnostic Schleimhautapplizierter impfstoff, der das adjuvanz chitosan und menigokokkenantigene enthält
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
EP1594536B1 (en) * 2003-01-30 2009-03-25 Novartis Vaccines and Diagnostics, Inc. Adjuvanted influenza vaccine
CN101926988B (zh) * 2003-01-30 2014-06-04 诺华疫苗和诊断有限公司 抗多种脑膜炎球菌血清组的可注射性疫苗
ATE506963T1 (de) 2003-10-02 2011-05-15 Novartis Vaccines & Diagnostic Kombinationsimpfstoffe gegen meningitis
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
AU2011224064A1 (en) * 2003-10-02 2011-10-06 Novartis Vaccines And Diagnostics S.R.L. Liquid vaccines for multiple meningococcal serogroups
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
PL1740217T3 (pl) 2004-04-30 2012-03-30 Novartis Ag Szczepienie koniugatem meningokokowym
AU2012203419B2 (en) * 2005-06-27 2014-06-26 Glaxosmithkline Biologicals S.A. Immunogenic composition
HUE031380T2 (en) * 2005-06-27 2017-07-28 Glaxosmithkline Biologicals Sa A method for producing vaccines
EP2068917A2 (en) * 2006-09-22 2009-06-17 Government of the USA, as Represented by the Secretary, Department of Health and Human Services Compositions and methods for chitosan enhanced immune response
PL2601969T3 (pl) * 2006-09-29 2016-10-31 Preparaty szczepionki przeciw norowirusowi
KR101562971B1 (ko) * 2007-04-06 2015-10-23 다케다 백신즈 인코포레이티드 살아있는 약독화된 바이러스를 위한 방법 및 조성물
US8916164B2 (en) * 2007-08-29 2014-12-23 Abivax Methods of enhancing adjuvaticity of vaccine compositions
US20100266636A1 (en) 2007-09-18 2010-10-21 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
KR20150129042A (ko) 2007-09-18 2015-11-18 다케다 백신즈 인코포레이티드 노로바이러스에 대한 보호면역반응을 제공하는 방법
SI2200642T1 (sl) * 2007-10-19 2012-06-29 Novartis Ag Formulacije meningokoknega cepiva
GB0822633D0 (en) * 2008-12-11 2009-01-21 Novartis Ag Formulation
EP3831406B1 (en) 2010-08-23 2024-06-05 Wyeth LLC Stable formulations of neisseria meningitidis rlp2086 antigens
AU2011300409B2 (en) 2010-09-10 2015-03-26 Wyeth Llc Non-lipidated variants of Neisseria meningitidis ORF2086 antigens
EP3299030B1 (en) 2011-07-11 2022-06-08 Takeda Vaccines, Inc. Parenteral norovirus vaccine formulations
MX351993B (es) 2012-03-09 2017-11-03 Pfizer Composiciones de neisseria meningitidis y metodos de las mismas.
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
US11229701B2 (en) * 2012-04-30 2022-01-25 Hibercell, Inc. Methods for identifying beta-glucan binding to immune cells
CA2903716C (en) 2013-03-08 2019-04-09 Pfizer Inc. Immunogenic fusion polypeptides
MX369534B (es) 2013-09-08 2019-11-11 Pfizer Composiciones de neisseria meningitidis y sus metodos.
RU2723045C2 (ru) 2015-02-19 2020-06-08 Пфайзер Инк. Композиции neisseria meningitidis и способы их получения
WO2018074296A1 (ja) * 2016-10-20 2018-04-26 一般財団法人化学及血清療法研究所 低分子化ＰＲＰを用いたＨｉｂコンジュゲートワクチンの製造方法
RU2727969C1 (ru) * 2016-11-08 2020-07-28 Колгейт-Палмолив Компани Композиции для ухода за полостью рта
JP7010961B2 (ja) 2017-01-31 2022-02-10 ファイザー・インク 髄膜炎菌組成物およびその方法
JP2022517981A (ja) * 2019-01-11 2022-03-11 ノースウェスタン ユニバーシティ 原核細胞溶解物におけるバイオコンジュゲートワクチンの合成
EP4153157A4 (en) * 2020-05-22 2024-06-05 Carlos Alberto Riveros SYSTEM, METHOD AND USE OF A CERTAIN DRUG FOR REDUCING VIRAL REPLICATION IN THE MUCS OF THE RESPIRATORY TRACT

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9422096D0 (en) 1994-11-02 1994-12-21 Biocine Spa Combined meningitis vaccine
GB9525083D0 (en) 1995-12-07 1996-02-07 Danbiosyst Uk Vaccine compositions
US6884435B1 (en) 1997-01-30 2005-04-26 Chiron Corporation Microparticles with adsorbent surfaces, methods of making same, and uses thereof
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
US7018637B2 (en) 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
CA2365296A1 (en) 1999-03-19 2000-09-28 Pierre Michel Desmons Vaccine
CA2366908A1 (en) * 1999-03-24 2000-09-28 The Secretary Of State For Defence Vaccine composition
GB9923060D0 (en) 1999-09-29 1999-12-01 Chiron Spa Vaccine
US20010026800A1 (en) 2000-01-07 2001-10-04 Michael Jacob G. Selective activation of a TH1 or TH2 lymphocyte regulated immune response
US20020156033A1 (en) 2000-03-03 2002-10-24 Bratzler Robert L. Immunostimulatory nucleic acids and cancer medicament combination therapy for the treatment of cancer
MXPA03000198A (es) 2000-06-29 2004-09-13 Glaxosmithkline Biolog Sa Composicion de vacuna multivalente.
GB0103170D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
GB0029919D0 (en) * 2000-12-07 2001-01-24 Chiron Spa Helicobacter pylori prime & boost vaccination
EP2332581B1 (en) 2001-01-23 2015-07-01 Sanofi Pasteur Inc. Tri- or tetravalent meningococcal polysaccharide-CRM197 conjugate vaccine
GB0107658D0 (en) * 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
WO2002080648A2 (en) 2001-04-05 2002-10-17 Chiron Corporation Mucosal boosting following parenteral priming
GB0115176D0 (en) * 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
WO2003028661A2 (en) * 2001-10-03 2003-04-10 Chiron Corporation Adjuvanted meningococcus compositions
GB0129007D0 (en) 2001-12-04 2002-01-23 Chiron Spa Adjuvanted antigenic meningococcal compositions
DE60331412D1 (de) 2002-01-14 2010-04-08 Novartis Vaccines & Diagnostic Hiv-vakzine und anwendungsverfahren
US7249709B2 (en) * 2002-03-18 2007-07-31 Koninklijke Philips Electronics N.V. Holder for papers of value, and method of registering the contents thereof
GB0302218D0 (en) * 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
WO2003094960A2 (en) 2002-05-14 2003-11-20 Chiron Srl Mucosal combination vaccines for bacterial meningitis

Also Published As

Publication number Publication date
RU2349342C2 (ru) 2009-03-20
ES2328128T3 (es) 2009-11-10
JP4696260B2 (ja) 2011-06-08
JP2016104813A (ja) 2016-06-09
AU2003233128B2 (en) 2008-10-09
CA2485992A1 (en) 2003-11-20
RU2004136299A (ru) 2006-03-10
CN100579580C (zh) 2010-01-13
RU2005127200A (ru) 2006-06-10
BR0310062A (pt) 2005-02-15
AU2003233128A1 (en) 2003-11-11
ES2470765T3 (es) 2014-06-24
EP1587538A1 (en) 2005-10-26
JP2015061879A (ja) 2015-04-02
US8926992B2 (en) 2015-01-06
WO2003094834A2 (en) 2003-11-20
EP1506008B1 (en) 2009-07-22
CN1767853A (zh) 2006-05-03
US20060051378A1 (en) 2006-03-09
CA2485992C (en) 2013-07-09
JP2005525415A (ja) 2005-08-25
EP1587538B1 (en) 2014-04-02
WO2003094834A3 (en) 2004-05-21
JP2012046550A (ja) 2012-03-08
NZ536715A (en) 2007-02-23
GB0302218D0 (en) 2003-03-05
BRPI0407101A (pt) 2006-01-24
EP1506008A2 (en) 2005-02-16

Similar Documents

Publication Publication Date Title
MXPA05007886A (es) Vacunas para la mucosa con adyuvante de quitosan y antigenos para meningococo.
WO2004067030A3 (en) Injectable vaccines against multiple meningococcal serogroups
WO2007071786A3 (en) Conjugate vaccines
MX348734B (es) Vacunacion multiple que incluye meningococcus del serogrupo c.
CA2435681A1 (en) Multivalent meningococcal polysaccharide-protein conjugate vaccine
CA2641585A1 (en) Capsular polysaccharide solubilisation and combination vaccines
TR201900418T4 (tr) Pnömokok polisakkarit konjugat aşısı.
HRP20120433T1 (en) Meningococcal vaccine formulations
EP1725872B8 (en) Analysis of saccharide vaccines without interference
RU2009134033A (ru) Жидкие вакцины для множественных серогрупп менингококков
JP2007516219A5 (es)
HUP0301413A1 (hu) Vakcinakészítmények
JP2005526847A5 (es)
WO2004103400A3 (en) Multivalent meningococcal derivatized polysaccharide-protein conjugates and corresponding vaccines
AP2004003074A0 (en) Adjuvanted antigenic meningococcal compositions
WO2005000345A3 (en) Immunization method against neisseria meningitidis serogroups a and c
WO2006034320A3 (en) Multivalent meningococcal derivatized polysaccharide-protein conjugates and vaccine
WO2006026689A3 (en) Multivalent meningococcal derivatized polysaccharide-protein conjugates and vaccine
NZ609888A (en) Multivalent meningococcal derivatized polysaccharide-protein conjugates and vaccine

Legal Events

Date Code Title Description
FG Grant or registration
HC Change of company name or juridical status

Owner name: HALLIBURTON MANUFACTURING AND SERVICES LIMITED